Last checked at 31 Mar 2022 15:50
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Block Listing 6 Monthly Return
Date: 31 March 2022
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics Retention Share Plan | |||
Period of return: | From: | 30 September 2021 | To: | 31 March 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 39,794 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 39,794 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
Period of return: | From: | 30 September 2021 | To: | 31 March 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 388,079 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | -47,059 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 341,020 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
Period of return: | From: | 30 September 2021 | To: | 31 March 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 24,273 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 24,273 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC | |||
Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
Period of return: | From: | 30 September 2021 | To: | 31 March 2022 |
Balance of unallotted securities under scheme(s) from previous return: | 3,178,276 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,178,276 | |||
Name of contact: | Lucy Huntington-Bailey |
Telephone number of contact: | +44 (0) 191 511 8500 |
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Greg Madison, CEO | +44 (0) 191 511 8500 |
Hans-Peter Rudolf, CFO |
|
Nominated Adviser and Joint Broker |
|
Peel Hunt LLP |
|
James Steel/Christopher Golden | +44 (0)20 7418 8900 |
Joint Broker finnCap Ltd Geoff Nash/Alice Lane/George Dollemore |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR (UK Advisor) |
|
Paul McManus/Lianne Applegarth/Alice Woodings
Investor Contact (US Advisor) | +44 (0)20 7933 8780 or shield@walbrookpr.com |
LifeSci Advisors, LLC John Mullaly
|
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
|
|
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Accrufer®/Feraccru®, has been approved for use in the United States, European Union, UK, Switzerland, and Australia and has exclusive IP rights until the mid-2030s. The Group has recently launched Accrufer® in the US. Feraccru® is being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Accrufer®/Feraccru® in China, Hong Kong, Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea and with KYE Pharmaceuticals Inc in Canada.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx